Trillium Therapeutics Provides Update on Its TTI-621 and TTI-622 CD47 Programs

Stock Information for OSE Immunotherapeutics

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About OSE Immunotherapeutics

TRILLIUM THERAPEUTICS PROVIDES BUSINESS UPDATE IN RESPONSE TO THE COVID-19 PANDEMIC
IIROC Trade Resumption - TRIL
IIROC Trading Halt - TRIL
IIROC Trade Resumption - TRIL
IIROC Trading Halt - TRIL
Trillium Therapeutics Announces Changes to Its Board of Directors
Trillium Closes US$117 Million Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares
Trillium Announces Pricing of US$101,700,000 Public Offering of Common Shares and Series II Non-Voting Convertible First Preferred Shares

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.